Phase II Amount
$1,478,293
A combination of DOD modernization priorities and supply chain assurance will require unprecedented development in production of new materials for tomorrows warfighter. The legacy chemical industry has assumed a paradigm of mega scale factories which has led to supply chain vulnerabilities due to centralization of manufacturing activity. On the other hand, biological manufacturing paradigm, with its origin in the pharma industry, offers advantageous positioning by enabling distributed smaller scale manufacturing. The proposed innovation constitutes development of semi-autonomous distributed production system for DOD relevant molecules.